Mason Street Advisors LLC bought a new stake in Parexel International Corp. (NASDAQ:PRXL) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 24,119 shares of the company’s stock, valued at approximately $1,517,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Aristotle Capital Boston LLC boosted its position in shares of Parexel International Corp. by 3.5% in the second quarter. Aristotle Capital Boston LLC now owns 156,770 shares of the company’s stock valued at $9,858,000 after buying an additional 5,298 shares during the period. Stifel Financial Corp acquired a new position in shares of Parexel International Corp. during the second quarter valued at about $370,000. Amalgamated Bank boosted its position in shares of Parexel International Corp. by 4.8% in the second quarter. Amalgamated Bank now owns 6,349 shares of the company’s stock valued at $440,000 after buying an additional 292 shares during the period. Legal & General Group Plc boosted its position in shares of Parexel International Corp. by 10.6% in the second quarter. Legal & General Group Plc now owns 15,819 shares of the company’s stock valued at $974,000 after buying an additional 1,514 shares during the period. Finally, Metropolitan Life Insurance Co. NY boosted its position in shares of Parexel International Corp. by 0.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 87,303 shares of the company’s stock valued at $5,490,000 after buying an additional 534 shares during the period. 96.13% of the stock is owned by hedge funds and other institutional investors.

Shares of Parexel International Corp. (NASDAQ:PRXL) opened at 67.37 on Monday. Parexel International Corp. has a 1-year low of $56.00 and a 1-year high of $73.62. The stock’s 50 day moving average is $68.15 and its 200-day moving average is $63.59. The stock has a market cap of $3.58 billion, a PE ratio of 23.56 and a beta of 0.95.

Parexel International Corp. (NASDAQ:PRXL) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.93 by $0.01. The firm earned $538.60 million during the quarter, compared to analysts’ expectations of $532.41 million. Parexel International Corp. had a net margin of 6.44% and a return on equity of 33.29%. Parexel International Corp.’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.79 EPS. On average, analysts predict that Parexel International Corp. will post $3.92 EPS for the current fiscal year.

Several research analysts recently issued reports on the stock. Evercore ISI reissued a “buy” rating and set a $78.50 target price (up previously from $71.00) on shares of Parexel International Corp. in a report on Friday, August 5th. Jefferies Group raised their target price on shares of Parexel International Corp. from $70.00 to $72.50 and gave the stock a “hold” rating in a report on Friday, August 5th. Deutsche Bank AG raised their target price on shares of Parexel International Corp. from $65.00 to $71.00 and gave the stock a “hold” rating in a report on Friday, August 5th. Citigroup Inc. raised their target price on shares of Parexel International Corp. from $74.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, August 5th. Finally, William Blair cut shares of Parexel International Corp. from an “outperform” rating to a “market perform” rating in a report on Monday, July 18th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $71.75.

In related news, insider Gadi Saarony sold 2,500 shares of the stock in a transaction on Monday, August 15th. The shares were sold at an average price of $70.05, for a total transaction of $175,125.00. Following the completion of the sale, the insider now owns 9,417 shares in the company, valued at approximately $659,660.85. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 2.70% of the company’s stock.

About Parexel International Corp.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.

5 Day Chart for NASDAQ:PRXL

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Parexel International Corp. (NASDAQ:PRXL).

Receive News & Ratings for Parexel International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parexel International Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.